和肝散对代偿性肝硬化的疗效及HA、LN、PCⅢ水平作用分析

摘要

目的:分析和肝散治疗代偿性肝硬化患者的临床疗效以及对患者血清透明质酸(HA)、层黏蛋白(LN)、前胶原Ⅲ(PCⅢ)表达水平的作用.方法:选取84例代偿性肝硬化患者为研究对象,随机均分为对照组与研究组,对照组给予拉米夫定治疗,研究组在对照组疗法的同时给予自拟和肝散治疗,治疗1疗程后评估对比两组临床疗效,观察治疗前后两组患者血清中HA、LN、PCⅢ表达水平的变化情况,统计两组治疗期间不良反应发生率以评估用药安全性.结果:对照组总有效率88.10%,研究组总有效率95.24%,研究组高于对照组(P<0.05).治疗后,两组较本组治疗前血清HA、LN、PCⅢ表达水平均有好转(P<0.05);研究组较对照组更为理想(P<0.05).对照组不良反应发生率14.29%,研究组不良反应发生率2.38%,研究组低于对照组(P<0.05).结论:自拟和肝散可有效提高代偿性肝硬化的临床疗效,降低患者血清H A、LN、PCⅢ表达水平.%Objective:To analyze the clinical efficacy of Hegan powder in the treatment of compensatory cir-rhosis and the effect of serum hyaluronic acid(HA),laminin(LN)and procollagen Ⅲ (PC III)expression level. Methods:84 cases of decompensated cirrhosis patients were as the research object,randomly divided into control group and study group,the control group was given lamivudine treatment,the study group was given at the same time the control group and the therapy with liver powder treatment,compared two groups of clinical curative effect evaluation after a course of treatment,observe the two groups before and after treatment in patients with HA,LN, PC Ⅲ changes in expression levels,statistics of the two groups during the treatment the incidence of adverse reac-tions to drug safety assessment.Results:The total effective rate of the control group was 88.10%,the total effec-tive rate of the study group was 95.24%,and that of the study group was higher than that of the control group(P<0.05).After treatment,the expression levels of serum HA,LN and PC Ⅲ were improved in the two groups com-pared with the level before treatment(P<0.05),the study group was more ideal than the control group(P<0. 05).The adverse reaction rate in control group was 14.29%,and the adverse reaction rate was 2.38% in study group,and that in study group was lower than that in control group(P<0.05).Conclusion:The Hegan powder can effectively improve the clinical efficacy of compensatory cirrhosis,and reduce the serum levels of HA,LN and PC Ⅲ expression.